How Digitalization is Revolutionizing French Healthcare
A physician sending off a quick update to a patient via smartphone; a medical caretaker receiving an alert message that a patient’s medical device requires immediate attention. These are no…
Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare.
The LFB Group is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are medicinal products derived from living organisms in three major fields of therapy: immunology, haemostasis and intensive care.
The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.
LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in nearly 60 countries.
Over 2000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients.
Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.
A physician sending off a quick update to a patient via smartphone; a medical caretaker receiving an alert message that a patient’s medical device requires immediate attention. These are no…
While assessing patient perspectives in comprehensive drug and treatment analyses may sound like a contemporary issue, the Mapi Group has been a pioneer in the practice for over forty years.…
Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of…
GEODIS MD Stéphanie Hervé speaks about the company’s consolidated pharmaceutical logistics market with the 2011 acquisition of pre-wholesaler Pharmalog as well as the recent acquisition of OHL in the United…
Mr Kimelfeld and Ms Labat run us through the exceptional history of Lyon and the region in the life sciences field, how Lyon is considered to be the birthplace of…
Pharmaceuticals do not appear in pharmacies and hospitals out of nowhere, yet the logistics of transporting these goods are a seldom acknowledged component of the healthcare industry supply chain. Behind…
PwC France’s pharma and life sciences industry leader speaks out about the consultancy’s positioning as partner of choice for advisory services in the pharmaceutical industry with more than 75 percent…
Sebastien Aguettant, president of the French Association of Pharmaceutical Contract Manufacturers (SPIS) and president of leading French CMO Delpharm, discusses the evolutions and growing significance of contract manufacturing, how CMO…
Genfit’s Jean-François Mouney speaks about responding to high unmet medical needs in inflammatory and metabolic related diseases. With the increase in obesity related diseases, Mouney discusses their lead pipeline product:…
Thépenier CEO Tsuyoshi Hasuo has imparted a unique vision to internationalize the Normandy-based French company encompassing a company turnaround and a maximization of growth potential. Together with Deputy CEO, Bertrand…
Eric Ducournau, CEO of Pierre Fabre Dermo-Cosmétique (PFDC), discusses the company’s revolutionary lines of dermatologically tested skincare products and their niche adapted internationalization strategy that is focused on providing the…
Growing awareness of start-up activity within France, fuelled by Minister for the Economy, Industry and Digital Affairs Emmanuel Macron’s ‘La French Tech program,’ is finally helping to place French start-ups…
See our Cookie Privacy Policy Here
